Confirmed Speakers already include:

Michael F Bigham, Partner, Abingworth Management
Dennis Purcell, Senior Managing Director, Aisling Capital
John Maraganore, President & CEO, Alnylam Pharmaceuticals
Dr Stefan Aigner, Executive Vice President, Corporate and Business Development, Alpharma, Inc.
Maggie LeFlore, PhD., Head, R&D Ventures, AstraZeneca Pharmaceuticals
Bruce Booth, Principal, Atlas Venture
Jesper Zeuthen, Senior Partner, BankInvest
Lewis C. Cantley, Professor of Systems Biology, Beth Israel Deaconess Medical Centre, Harvard Medical School
Mark Wiggins, EVP, Corporate and Business Development, Biogen Idec
Dr Masamichi Koike, President & CEO, BioWa
Scott Kirsner, Innovation Economy Columnist, Boston Globe & Co-Founder of the Convergence Forum
Jeremy Levin, Senior Vice President, Bristol-Meyers Squibb
Robert Schwartz, Senior Director Oncology Licensing, Bristol-Meyers Squibb
Steven Dickman, Chief Executive Officer, CBT Advisors
Tim Surgenor, President & CEO, Cyberkinetics Neurotechnology Systems, Inc.
Brian Halak, Partner, Domain Associates LLC
Al Sokol, Partner, Edwards Angell Palmer & Dodge
Bill Mills, Managing Member, EGS Healthcare
Dr George A Scangos, President & Chief Executive Officer, Exelixis
Dr Gottfried Himmler, CEO & Managing Director, f-star
Dr Stephen Knight, Managing Partner, Fidelity Biosciences
Doug Cole, General Partner, Flagship Ventures
Stan Yakatan, Chairman, Katan Associates
Arthur T Sands, President & CEO, Lexicon Pharmaceuticals
Tamar D Howson, Executive Vice President of Business Development, Lexicon Pharmaceuticals
Dr Scott Koenig, President & CEO, Macrogenics
John Brooks III, President & CEO, Medical Capital Advisors, LLC
Dr Reid Leonard, Executive Director Licensing and External Research, Merck & Co
John T Santini Jnr, President & CEO, MicroCHIPS, Inc.
Ansbert Gadicke, General Partner, MPM Capital
Dr Corinne Savill, Business Development and Licensing, Global Head Search and Evaluation, Novartis Pharma
Markus Goebel, Partner, Novartis Venture Fund
Ulrik Spork, Partner, Novo A/S
Stuart Barich, Managing Director, Opppenheimer & Company
Doug Fambrough, Partner, Oxford Bioscience Partners
Jonathan Fleming, Managing Partner, Oxford Bioscience Partners
Michael Lytton, General Partner, Oxford Bioscience Partners
Dr Robert Bagdorf, Executive Director Licensing & Development, Pfizer Inc.
Dr Lutz Giebel, Managing Partner, SV Life Sciences
Robert Urban, Executive Director, The David H. Koch Institute for Integrative Cancer Research
Dr Jens Eckstein, Partner, TVM Capital

Themes >>>